Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma.
Future Oncol
; 12(5): 637-45, 2016 Mar.
Article
em En
| MEDLINE
| ID: mdl-26837701
ABSTRACT
AIM:
To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma. MATERIALS &METHODS:
Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation.RESULTS:
All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years.CONCLUSION:
Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Renais
/
Radiocirurgia
/
Neoplasias Renais
Tipo de estudo:
Diagnostic_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Austrália